Fluralaner goes global: 88,486 US adverse-event reports as China approves a domestic spot-on in 2026
The same molecule tells two very different stories depending on which ocean you stand on. In the United States, fluralaner — the isoxazoline-class ectoparasiticide sold under the Bravecto banner — has accumulated 88,486 adverse-event reports in the FDA's database. In China, a domestic manufacturer in 2026 won approval for a home-grown equivalent, Fluolaner (氟雷拉纳 / fluralaner), landing a new veterinary drug certificate and a four-year monitoring period. One molecule, two clocks: a mature, heavily reported market on one side, and a freshly opened regulatory door on the other.
One molecule, two clocks
Fluralaner is a veterinary active ingredient and an isoxazoline ectoparasiticide (flea/tick). It has been on the US market for years and keeps gaining new indications there. Across the Pacific, the Chinese Ministry of Agriculture and Rural Affairs (农业农村部, MOA) only entered fluralaner into its domestic pet pharmaceutical catalogue in 2026. The gap is not about safety or efficacy per se — it is about where the molecule sits on its life cycle. The US side is in the "count the reports" phase; the China side is in the "grant the certificate" phase.
The US signal: 88,486 reports
In the FDA Center for Veterinary Medicine (CVM) adverse-event database, drawn from openFDA animalandveterinary/event.json, fluralaner totals 88,486 reports. By species, the breakdown is led by Dog 65708 and Cat 13343, with Human 1288 also reported.
The top reported reactions, listed in VEDDRA terms, are headed by Vomiting 20360, then Lack of efficacy (ectoparasite) - flea 17108, Emesis (multiple) 6345, Lethargy (see also Central nervous system depression in 'Neurological') 6117, Lack of efficacy (ectoparasite) - tick NOS 5244, Diarrhoea 4741, UNPALATABLE 4069, Seizure NOS 3347, Application site hair loss 2487, and Product Defect, General 2323.
The neurological signal is the one that draws scrutiny: Seizure NOS 3347 sits among the top reported reactions. For cats specifically, fluralaner also shows up as a heavily reported active. In the cat-specific slice of the database — which itself totals Cat: 148091 adverse-event reports — the active Fluralaner Spot-On Solution 10109 ranks fourth behind Selamectin 21951, Spinosad 11858, and Praziquantel 10409.
The China signal: a domestic equivalent in 2026
On 2026年5月14日 (May 14, 2026), the MOA issued MOA Announcement No. 1022 (农业农村部公告第1022号). Among six new veterinary drugs, it approves Fluolaner (氟雷拉纳) — new active pharmaceutical ingredient (新活性成分) at Category 2 (二类), registration certificate (2026)新兽药证字50号, with a Monitoring period (监测期) | 4 years (4年). The paired finished product, Fluolaner Drops (氟雷拉纳滴剂), a pet topical ectoparasiticide, is approved at Category 2 (二类) under certificate (2026)新兽药证字51号, again with a 4 years (4年) monitoring period. Research units listed include 山东鲁抗舍里乐药业有限公司 and 兰州大学.
Fluralaner (氟雷拉纳) is described in the source as an isoxazoline-class ectoparasiticide; the drops formulation (滴剂) is intended for topical application on companion animals (犬/猫). The consolidated 2026 timeline frames this as part of a broader wave: Announcement No. 1022 carries certificate numbers 50–55号, and the approvals run consecutively through No. 1040 (January–July 2026). The timeline notes that Fluolaner (氟雷拉纳, 证字50–51号) is an isoxazoline-class compound registered as a novel pet ectoparasiticide.
Bravecto: still expanding in the US
While China was issuing certificate 50–51号, the originator brand in the US kept widening its footprint. The FDA Green Book "Recent Animal Drug Approvals" pet-drug slice covers the period 2024-11-06 to 2026-06-29 and lists 8 BRAVECTO-line entries (incl. PLUS / QUANTUM / 1-MONTH). Representative fluralaner approvals there:
- Nov 25, 2024 — BRAVECTO 1-MONTH (fluralaner), Dogs, "Kills Asian longhorned ticks for 1 month."
- Jul 10, 2025 — BRAVECTO® QUANTUM (first approval), Dogs, "12 months of flea + tick protection."
- Jan 13, 2026 — BRAVECTO® PLUS (fluralaner + moxidectin), Cats, "Kills Gulf Coast ticks for 2 months."
- Mar 16, 2026 — BRAVECTO® QUANTUM (fluralaner injectable), Dogs, "Asian longhorned tick + Gulf Coast tick, 12 months."
- Jun 12, 2026 — BRAVECTO® (fluralaner topical solution), Cats, "Kills Gulf Coast ticks for 12 weeks; kittens ≥12 weeks, ≥2.6 lbs."
The dominant theme of these new indications is the response to invasive tick species: the Asian longhorned tick (Haemaphysalis longicornis) drew "5+ new indications (BRAVECTO / BRAVECTO QUANTUM / BRAVECTO 1-MONTH / Simparica / Simparica TRIO / NexGard)" and the Gulf Coast tick (Amblyomma maculatum) drew "4 new indications (BRAVECTO / BRAVECTO QUANTUM / BRAVECTO PLUS / NexGard)." Outside the US, the molecule is also a registered, marketed product: Health Canada's Drug Product Database records a BRAVECTO entry — verbatim row Marketed,02425068,Dogs,INTERVET CANADA CORP,BRAVECTO,Veterinary,Yes,PRESCRIPTION,1,FLURALANER,112.5 MG — confirming FLURALANER at 112.5 MG for Dogs.
Reading the gap
The contrast is structural, not contradictory. The US reports are the exhaust of a molecule that has been widely used for years and keeps gaining indications; the China certificate is the starting gun for a domestic equivalent. A four-year monitoring period (监测期) means Chinese regulators are explicitly building the post-approval surveillance track that, on the US side, has already produced tens of thousands of entries. Neither number proves the molecule is uniquely dangerous or uniquely safe — they sit at different points on the same timeline.
Data disclaimer (read before citing the numbers)
All adverse-event report counts in this article are cumulative values as of the openFDA pull snapshot dated 2026-07-21/22 (the underlying topics were pulled on 2026-07-21 and 2026-07-22 and both report the same total of 88,486). These figures are reported, not confirmed causal — a report to FDA CVM does not establish that fluralaner caused the reaction. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Under the VEDDRA framing used by the source, terms such as "Lack of efficacy (ectoparasite) - flea" and "Lack of efficacy (ectoparasite) - tick NOS" denote product-performance reports, not adverse reactions, and should not be read as safety signals. The Chinese approval data describe a regulatory status (new veterinary drug registration, class, monitoring period), not a safety or efficacy finding.
Sources
Every figure above is a verbatim substring of the following source topics (petfood-data-station web/topics):
ade_fluralaner_adverse_events— "fluralaner: 88486", "Dog 65708", "Cat 13343", "Human 1288", "Vomiting 20360", "Seizure NOS 3347", "Lack of efficacy (ectoparasite) - flea 17108"; openFDA pull 2026-07-21.ade_fluralaner(companion ADE topic) — confirms "Fluralaner: 88486" at openFDA pull 2026-07-22.ade_top_actives_cat— "Cat: 148091", "Fluralaner Spot-On Solution 10109", "Selamectin 21951", "Spinosad 11858", "Praziquantel 10409"; openFDA pull 2026-07-22.cn_moa_ann1022_new_veterinary_drugs_pet— MOA Announcement No. 1022 (2026-05-14); "Fluolaner (氟雷拉纳) ... Category 2 (二类) ... (2026)新兽药证字50号 ... 4 years (4年)"; "Fluolaner Drops (氟雷拉纳滴剂) ... (2026)新兽药证字51号 ... 4 years (4年)"; isoxazoline-class ectoparasiticide.cn_moa_pet_veterinary_drugs_timeline_2026— 2026 timeline (Announcements 1022–1040); Fluolaner (氟雷拉纳) certificate 50–51号, Category 2 (二类), 4 years (4年), isoxazoline-class novel pet ectoparasiticide.fda_green_book_recent_approvals_pet_drug_2024_2026— pet-drug slice 2024-11-06 to 2026-06-29; BRAVECTO-line entries (1-MONTH 2024-11-25, QUANTUM 2025-07-10 and 2026-03-16, PLUS 2026-01-13, fluralaner topical solution 2026-06-12); "8 BRAVECTO-line entries"; Asian longhorned tick and Gulf Coast tick indication roll-ups.approval_label_bravecto— Health Canada DPD verbatim rowMarketed,02425068,Dogs,INTERVET CANADA CORP,BRAVECTO,Veterinary,Yes,PRESCRIPTION,1,FLURALANER,112.5 MG.